Current Status of New Anticoagulants in the Management of Venous Thromboembolism
Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and proph...
Saved in:
Main Authors: | Roberto C. Montoya, Ajeet Gajra |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2012/856341 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Global Research Hotspots in Venous Thromboembolism Anticoagulation: A Knowledge-Map Analysis from 2012 to 2021
by: Jia Wang, et al.
Published: (2023-01-01) -
Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in nephrotic syndrome patients: a retrospective study
by: Ahmed El-Bardissy, et al.
Published: (2025-01-01) -
Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review
by: Atheer G. Almutairi, et al.
Published: (2025-01-01) -
Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
by: Olivia Wu, et al.
Published: (2022-01-01) -
Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
by: Maria I. Zervou, et al.
Published: (2025-02-01)